BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (“HA”) technology, today reported record revenue for the year ending December 31, 2007. Anika also continued to strengthen its global position in joint health therapies with the recent launch in Europe of ORTHOVISC®mini, a HA osteoarthritis treatment specifically targeted for smaller joints, and the commencement of a key U.S. clinical study of its single-injection osteoarthritis product, MONOVISC™, for the relief of knee pain.
